Drug intelligence / Profile preview

BMND08

Development stage: Unknown
Lead developer: Biomind Labs
Modality: Small Molecules
Administration: Sublingual

Overview

BMND08 is a proprietary 5-Metoxi-N,N-dimethyltryptamine (5-MeO-DMT)-based sublingual formulation developed by Biomind Labs for the treatment of depression and anxiety in Alzheimer's disease. The drug is designed to be cost-effective, scalable, and non-invasive. In Phase II clinical trials, BMND08 demonstrated significant improvements in depression, anxiety, and stress scores compared to placebo, with patients showing notable enhancements in executive functions, particularly in processing speed. The maximum safe, tolerable, and non-psychedelic dose was established at 12mg, administered once weekly over four consecutive weeks.

Other names: 5-MeO-DMT sublingual formulation

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on BMND08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMND08.

Explore the full profile